TransCode Therapeutics Receives $2M NIH Grant for Lead Candidate Clinical Evaluation

TransCode Therapeutics, Inc., an RNA oncology company, has announced receiving a significant grant of $2 million from the National Cancer Institute of the NIH. This funding, awarded under the Direct to Phase II Small Business Innovation Research (SBIR) program, will support the clinical evaluation of TransCode's leading therapeutic candidate, TTX-MC138.

Recently, TransCode initiated three clinical trial sites to conduct a Phase I/II clinical trial for TTX-MC138 aimed at treating advanced solid tumors. The primary goal of this clinical trial is to gather essential data concerning the safety of TTX-MC138. Although the trial's primary endpoint is not to determine the efficacy, it could potentially provide early signs of TTX-MC138's clinical activity in patients suffering from metastatic diseases. The grant funds are anticipated to be distributed over a two-year period.

Dr. Zdravka Medarova, Chief Scientific Officer at TransCode, expressed appreciation for the NIH's continued support and recognition of their mission to advance therapies targeting metastatic cancer. According to Dr. Medarova, the rigorous review process associated with NIH funding signifies the potential impact, novelty, and robustness of TransCode's clinical development program for TTX-MC138.

TTX-MC138 is a pioneering therapeutic candidate with distinctive relevance to metastatic diseases. Should the clinical development of TTX-MC138 be successful, it could offer a viable treatment option for numerous patients battling metastatic cancer.

TransCode Therapeutics is a clinical-stage oncology company with a focus on treating metastatic diseases. The company is dedicated to combating cancer through the intelligent design and effective delivery of RNA therapeutics, leveraging its proprietary TTX nanoparticle delivery platform. The company's primary therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker associated with metastasis. Besides TTX-MC138, TransCode is developing a portfolio of other first-in-class RNA therapeutic candidates designed to address the challenges of RNA delivery, aiming to unlock therapeutic access to various novel genetic targets that could be crucial in treating multiple types of cancer.